Tratamento com bimekizumabe em pacientes com espondiloartrite axial ativa: eficácia e segurança após 52 semanas nos estudos randomizados e paralelos de fase 3 BE MOBILE 1 e BE MOBILE 2
Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803
Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.